NCT04236479View on ClinicalTrials.gov

Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Congenital Heart Disease (CHD)
Interventions
BIOLOGICAL

BM-MSC

Allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery through cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life.

Trial Locations (1)

20010

Children's National Health System, Washington D.C.

All Listed Sponsors
lead

Catherine Bollard

OTHER